AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said late Wednesday that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product

Read the full 350 word article

User Sign In